TLR9 and pertussis: Addition of a TLR9 agonist to the acellular pertussis vaccine resulted in greater stimulation of B and T cells and a shift to Th1, as well as higher antibody titers (81, 170–174), suggesting that an agonist of TLR9 is also a candidate to add to the current pertussis vaccines.